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Improving the power of clinical trials of rheumatoid
arthritis by using data on continuous scales when
analysing response rates: an application of the
augmented binary method
James M. S. Wason1 and Martin Jenkins2
Abstract
Objective. In clinical trials of RA, it is common to assess effectiveness using end points based upon
dichotomized continuous measures of disease activity, which classify patients as responders or non-
responders. Although dichotomization generally loses statistical power, there are good clinical reasons
to use these end points; for example, to allow for patients receiving rescue therapy to be assigned as non-
responders. We adopt a statistical technique called the augmented binary method to make better use of
the information provided by these continuous measures and account for how close patients were to being
responders.
Methods. We adapted the augmented binary method for use in RA clinical trials. We used a previously
published randomized controlled trial (Oral SyK Inhibition in Rheumatoid Arthritis-1) to assess its perform-
ance in comparison to a standard method treating patients purely as responders or non-responders. The
power and error rate were investigated by sampling from this study.
Results. The augmented binary method reached similar conclusions to standard analysis methods but
was able to estimate the difference in response rates to a higher degree of precision. Results suggested
that CI widths for ACR responder end points could be reduced by at least 15%, which could equate to
reducing the sample size of a study by 29% to achieve the same statistical power. For other end points,
the gain was even higher. Type I error rates were not inflated.
Conclusion. The augmented binary method shows considerable promise for RA trials, making more
efficient use of patient data whilst still reporting outcomes in terms of recognized response end points.
Key words: biostatistics, methodology, randomized controlled trials, rheumatoid arthritis.
Rheumatology key messages
. Trials of RA treatments frequently use composite end points consisting of continuous and discrete
subcomponents.
. Typical analyses of RA trials ignore information contained in the continuous subcomponent of composite end
points.
. The augmented binary method better models composite end points and thereby improves power in RA trials.
Introduction
Clinical trials in RA commonly report end points based
upon assigning patients as either a responder or a non-
responder to treatment according to measures of disease
activity. In these so-called responder analyses, informa-
tion recorded on a continuous scale is dichotomized and
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reduced down to a single binary outcome based upon
whether patients reach a defined goal. This may be the
case both for levels of improvement from baseline (e.g.
ACR responder end points or HAQ-DI change from base-
line) or for absolute measures of disease activity (such as
DAS28, SDAI or CDAI; see Table 1). Such summaries use
only the information about whether a patient’s disease
activity levels are above or below a given threshold and
discard information about the exact result or how far
above or below this threshold the patient may lie. These
analyses are therefore statistically inefficient and fail to
make the maximal use of the data available, as has
been well recognized in the statistical literature [1, 2], as
well as in RA trials specifically [37].
Although most outcomes can be analysed on a continu-
ous scale, the average change in a variable at a group
level may not tell the rheumatologist how many patients
have reached a meaningful level of improvement or at-
tained a given disease activity target. This may be particu-
larly relevant when practising a treat-to-target approach
[8]. For this reason, reporting the proportion of patients
achieving a minimal clinically important difference in the
reduction in a patient-reported outcome, for example,
may be clinically desirable in addition to purely presenting
the mean change from baseline. The rheumatologist may
also be more familiar with the response rates that they
would expect to see for measures such as ACR20 [9],
ACR50 and ACR70 rather than having an appreciation of
what a desirable median ACR-N result [6] might be.
Alternative outcomes, such as hybrid ACR [4], have
been suggested, but have challenging distributional prop-
erties. There are therefore benefits to retaining the use of
outcomes that are familiar to the rheumatology commu-
nity, despite the statistical limitations of responder
analyses.
Another benefit of responder analyses is that they can
naturally incorporate other information into the response
definition. Commonly used examples include assigning
patients as non-responders if they have changes to back-
ground medications or doses, if they have rescue medi-
cations administered or if they discontinue treatment.
Such an analysis answers a relevant question of how
many patients can achieve meaningful clinical targets
while tolerating an assigned treatment and without resort-
ing to changes in background steroid or DMARD admin-
istration. Therefore, although withdrawal or rescue are not
formally considered part of the definition of ACR20 re-
sponse, typical non-responder analyses are effectively al-
ready estimating outcomes built from both continuous
and binary components, as is done in the present study.
This non-responder imputation for responder analyses is
well established and accepted by regulators for RA trials.
In contrast, the handling of missing data when working on
the continuous scale is still subject to much current
debate [10].
A disease area that shares similar composite end points
to RA is solid tumour oncology. Patients are classed as
responders if their tumour size shrinks by a prespecified
level and they do not have new lesions. In that case, the
augmented binary method [11] was proposed to maintain
the clinically relevant responder end points but improve
the precision of analyses. Compared with treating the out-
come as a binary yes-or-no outcome, the augmented
binary method provides a large gain in efficiency. This
gain comes from the avoidance of classifying patients
purely as a responder or a non-responder. Instead, it
uses a suitable statistical model to account for how
close patients were to being a responder.
In the present study, we propose using a similar ana-
lysis method in order to make full use of the continuous
information collected from patients in clinical trials in RA
while at the same time continuing to use well-recognized
and understood outcomes. To illustrate the benefits of
such an approach, we use the Oral SyK Inhibition in
Rheumatoid Arthritis (OSKIRA-1) study [12] and consider
ACR and DAS28 end points. We demonstrate that the
method does not inflate the type I error rate and show
that it substantially improves the power of analyses.
Methods
Description of the OSKIRA-1 study
The OSKIRA-1 study (NCT01197521) was a multicentre,
randomized, double-blind, placebo-controlled (for 24
weeks) parallel-group study to investigate the efficacy
and safety of fostamatinib in RA patients with active
TABLE 1 Examples of dichotomized responder end points used in clinical trials of RA
Continuous
end point Responder end point
Absolute or relative
to baseline Thresholds typically used
ACR-N ACR20, ACR50, ACR70 Relative to baseline 20%, 50%, 70%
DAS28 Remission, low disease activity,
moderate disease activity
Absolute disease activity 2.6, 3.2, 5.1
SDAI 3.3, 11, 26
CDAI 2.8, 10, 22
HAQ-DI HAQ-DI response, according to
minimally important difference
Relative to baseline 0.22, 0.25, 0.3
(various thresholds used)
SDAI: simple disease activity index; CDAI: clinical disease activity index; HAQ-DI: Health assessment questionnaire disability
index.
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disease despite current treatment with MTX. The OSKIRA-
1 study involved 141 centres in 17 countries. The final
clinical study protocol and protocol amendments, includ-
ing the final version of the informed consent form and any
other written information and/or materials to be provided
to the patients, was approved or given a favourable opin-
ion in writing by an Independent Ethics Committee for
each study centre.
Before enrolment of any patient into the study, the final
clinical study protocol, including the final version of the
informed consent form, was approved by the national
regulatory authority or a notification to the national regu-
latory authority was done, according to local regulations.
All patients provided written informed consent. Nine hun-
dred and eighteen patients were randomized and received
at last one dose of study drug. Patients were randomized
(1:1:1) to receive fostamatinib 100 mg twice daily, fosta-
matinib 100 mg twice daily for 4 weeks and then 150 mg
once daily, or placebo, on a background of MTX treat-
ment. The trial was blinded for 52 weeks, with placebo
patients switching to fostamatinib treatment at week 24
or at week 12 if requiring early rescue. In the present
study, we consider only the period up to the primary
end point at week 24. In the co-primary analyses, a stat-
istically significant difference in ACR20 response rates
was seen compared with placebo for both doses, but nei-
ther dose demonstrated statistical significance in radio-
graphic scores. The results of this study have been
reported previously [12] and were not deemed sufficient
to seek regulatory submission in RA upon programme
completion. The study is used here to illustrate the new
methodology, with no intention to challenge the conclu-
sions of the original analyses.
RA end points
We consider the ACR and the DAS28 end points, using
CRP as the acute phase reactant [13]. In all cases, the end
point is classified based on data up to and including 24
weeks.
For the ACR end points, we define response according
to the ACR20, ACR50 and ACR70 categorization. In each
case, the patient is classed as a responder if they dem-
onstrate a given percentage improvement in their swollen
joint count, tender joint count and three of the five remain-
ing core set measures. This is exactly equivalent to defin-
ing a patient as a responder if their ACR-N score [6] was
greater than or equal to the relevant threshold (20, 50 and
70, respectively) at 24 weeks. Applying non-responder
imputation, the patient must reach this threshold without
having been withdrawn, had background medication
changes or been given rescue therapy. As such, it is pos-
sible to model the ACR outcomes using an equivalent
underlying model of ACR-N.
For the DAS28 end points, patients were similarly clas-
sified as a responder if their DAS28 score at 24 weeks was
below an absolute threshold (2.6 or 3.2) and they had not
been withdrawn, had background medication changes or
been given rescue therapy.
Augmented binary method
A full technical description of the notation and method-
ology used for the augmented binary method is given in
the supplementary methods, available at Rheumatology
Online. The augmented binary method can be used to
analyse any composite outcomes that consist of a con-
tinuous component (e.g. any of the ones in Table 1). It
provides an estimate of the difference in probability of a
patient being a responder between two treatment arms.
For the ACR outcomes, we consider the ACR-N score
at 12 weeks, the ACR-N score at 24 weeks and variables
which record whether a patient was withdrawn from treat-
ment or given rescue therapy. For the DAS28 outcomes,
we consider the DAS28 score at 12 weeks, the DAS28
score at 24 weeks and the withdrawal/rescue variables.
In both cases, a continuous generalized estimating equa-
tion model is fitted to the relevant score at 12 and 24
weeks, which is adjusted for treatment arm and baseline
DAS28 score. A logistic regression model is fitted to
model the probability of a patient being withdrawn from
treatment or given rescue therapy between baseline and
12 weeks; a second logistic regression model is used to
model the probability of withdrawal or rescue therapy be-
tween 12 and 24 weeks. In the former case, the treatment
arm and baseline DAS28 score are included as covariates
in the model; in the latter case, the treatment arm and
outcome score at 12 weeks are included as covariates.
Additional covariates can also be adjusted for if desirable.
The augmented binary method then combines these
three models in order to estimate various quantities of
interest that compare the response probabilities between
arms, such as the difference or odds ratio. Importantly, it
also provides CIs, allowing one to test for a significant
difference between arms. In the present manuscript, we
present the difference in response probabilities, but
equivalent details for the odds ratio and the ratio of re-
sponse probabilities are provided in supplementary
Tables S1 and S2, available at Rheumatology Online.
Comparison method
We compared the augmented binary method with a more
standard method that treats the overall composite end
point as a binary outcome. As with the augmented
binary method, those patients who withdrew or received
rescue medication were treated as non-responders. We
fitted logistic regression models to the overall responder/
non-responder indicator. To ensure that the comparison
was fair, we included the baseline DAS28 score as a cov-
ariate as well as the treatment arm. The method for doing
this is described further in the supplementary methods,
available at Rheumatology Online. This is referred to
henceforth as the standard binary method.
Analyses
The augmented binary method has previously been as-
sessed on simulated data and a small phase II cancer
trial [11]. In the present analysis, we base all assessment
of its performance on the OSKIRA-1 study. We first
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present the results of analysing the trial using standard
and augmented binary methods.
Second, we sought to determine whether the aug-
mented binary method causes any inflation in the type I
error rate. We sampled a total of 5000 replicate data sets
based on the OSKIRA-1 data; in each data set, the treat-
ment assignment variables were randomly shuffled. This
simulates the situation where there is no difference in the
effectiveness of the two treatment arms. Each replicate
data set was then analysed using both methods, and
the estimated treatment effect and 95% CI were re-
corded. The type I error rate was estimated as the pro-
portion of replicates in which the 95% CIs did not contain
zero. Assuming the method does not cause problems with
the type I error rate, this proportion should be close to 5%.
From these replicates, we also recorded the width of the
CIs. If the augmented binary method improves the power
of RA trials, then the CI width should be narrower on aver-
age than that of the standard binary method.
A third analysis examined the power of the two methods
for smaller trials. We varied the size of trial considered
from 100 to 300 in increments of 10. For each size, 5000
replicates were generated. In each replicate, the specified
number of patients was randomly sampled without re-
placement from the OSKIRA-1 data set, and both meth-
ods were applied to the resulting data set. The estimated
treatment effect difference and 95% CI were recorded.
The proportion of CIs that did not contain zero was used
to estimate the power of both methods. In addition, we
examined the correlation between the estimated treat-
ment effect from both methods for a trial size of 200.
Results
Analysis of OSKIRA-1 data set
Table 2 shows the results from the original OSKIRA-1 data
set. For all ACR and DAS28 categorizations, the three
treatment effect summaries were found using the stand-
ard binary and augmented binary methods. The results
show that for individual data sets, the two methods can
give moderately different estimated treatment effects.
However, the estimates for the augmented binary
method remain within the bounds of the CI of the standard
methods (and vice versa). In the case of ACR20, the aug-
mented binary method gives a higher estimated difference
between arms (19% compared with 13% with the stand-
ard binary method). For ACR50, ACR70 and the two
DAS28 end points, the standard binary method gives
higher estimated differences, but with response rates gen-
erally differing between methods by only 2%. In all
cases, the CI from the two methods overlaps, usually sub-
stantially. There were no disagreements between the two
methods in whether statistical significance was reached;
thus, the conclusions of the OSKIRA-1 study would not
have been affected from the use of the augmented binary
method.
Table 2 also shows that the CI width is narrower for the
augmented binary method, indicating that it gives a more
precise estimate of the probability of response.
Type I error rate
Table 3 shows the results of both methods when permu-
tation testing was used to simulate no difference between
arms. In all cases, the estimated type I error rate of the
augmented binary method was consistent, with the true
value being 5%. In most cases, the standard binary
method had the correct type I error rate; for the difference
in response probabilities outcome for DAS28<3.2, there
was evidence of a small inflation. There was no evidence
of inflation when the odds ratio was used, so we conclude
that the inflation here is most likely to be because of the
delta-method used to convert from odds ratios to the dif-
ference in response probabilities. These results indicate
that there is no evidence of type I error rate inflation for the
augmented binary method when realistic data are used.
Table 3 also shows the average width of the CIs. In all
cases, the augmented binary method reduces the average
CI width compared with the standard binary method. As
an illustration of the gain in efficiency, on average the
estimated difference in ACR20 response rate between
treatments would be known to ±7.9% with the standard
binary method but to ±6.6% with the augmented binary
method. This 15.8% reduction in CI width is equivalent to
the augmented binary method requiring a 29.1% lower
sample size for the same power. The reduction in width
for other end points is even higher, which means even
TABLE 2 Analysis of ACR and DAS28 end points in the OSKIRA-1 data set
Standard binary method Augmented binary method
End point
Fostamatinib
100 mg response
rate
Placebo
response
rate
Difference
(95% CI)
Fostamatinib
100 mg response
rate
Placebo
response
rate
Difference
(95%CI)
ACR20 0.47 (0.42, 0.53) 0.34 (0.29, 0.39) 0.13 (0.05,0.21) 0.53 (0.49, 0.58) 0.34 (0.29, 0.39) 0.19 (0.13, 0.26)
ACR50 0.23 (0.18, 0.27) 0.08 (0.05, 0.11) 0.15 (0.09,0.20) 0.26 (0.22, 0.30) 0.13 (0.10, 0.16) 0.13 (0.08, 0.18)
ACR70 0.10 (0.06, 0.13) 0.02 (0.00, 0.04) 0.08 (0.04,0.11) 0.10 (0.09, 0.12) 0.04 (0.03, 0.05) 0.06 (0.04, 0.08)
DAS28 <3.2 0.26 (0.21, 0.30) 0.11 (0.07, 0.14) 0.15 (0.09,0.21) 0.25 (0.21, 0.28) 0.12 (0.09, 0.14) 0.13 (0.08, 0.17)
DAS28 <2.6 0.13 (0.09, 0.16) 0.05 (0.02, 0.07) 0.08 (0.04,0.12) 0.12 (0.10, 0.15) 0.05 (0.04, 0.06) 0.07 (0.05, 0.10)
The values are the response rate (i.e. proportion of patients who respond) and 95% CIs in parentheses.
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more dramatic reductions in sample size for the same
target power. It is these higher hurdle outcomes, such
as ACR70 and DAS28< 2.6, that are more typically lack-
ing statistical power in clinical studies and thus where
gains in precision could provide the most benefit.
Subsamples of OSKIRA-1 data set
In order to examine the power of the two methods further,
we examined more closely the DAS28<2.6 end point,
where the estimated treatment effect was similar between
the two methods. By sampling smaller numbers of indi-
viduals repeatedly, we plotted the estimated power for
different numbers of patients.
For the case where 200 patients were sampled, Fig. 1
shows a scatter plot representing the estimated treatment
effect (in terms of the difference in response probability
between arms) from the two different methods for each
replicate. It shows that there is a moderately strong cor-
relation between estimates (Pearson correlation coeffi-
cient 0.629, 95% CI: 0.612, 0.646). This indicates that
the methods reach similar conclusions but may give mod-
erately different estimates for some individual data sets.
Where the estimate given by the augmented binary
method differs from that given by the standard binary
method, this is more often because the augmented
method is giving an estimate closer to its mean from
across all the replicates. This may indicate the fact that
the augmented binary method is less prone to producing
chance outlying results.
Figure 2 shows the power of the two methods as the
sample size changes. The augmented binary method pro-
vides a large gain in power for this example data set and
end point across the different sample sizes considered.
As an example, if hypothesizing that the response rates
observed in this study would be seen in a future study, a
sample size of 300 would be required for 80% power at
5% two-sided type I error rate to demonstrate a signifi-
cant difference with the standard binary method. To
achieve the same power with the augmented binary
method, 130 patients are required. This corresponds
well to results from the type I error rate investigation,
where using the augmented binary method for the
DAS28 end point resulted in a large reduction in CI width.
Discussion
We have shown that widely used binary end points in RA
can be estimated considerably more precisely when the
nature of the end point, being based upon the
dichotomization of a continuous score, is taken into ac-
count. By using our proposed augmented binary method,
the response rates for ACR and DAS28 end points could
be estimated to the same degree of precision (i.e. same CI
width) as the standard binary approach but using a much
smaller sample size. The method does not cause any in-
flation to the type I error rate and can be implemented in a
straightforward manner in standard statistical software
packages, such as R (see https://sites.google.com/site/
jmswason/supplementary-material for downloadable
TABLE 3 Type I error rate and CIs for standard and augmented binary methods
Statistical property
Difference
Standard binary (%) Augmented binary (%)
ACR20
Type I error rate (%) 5.1 5.1
Average width of CI 15.7 13.2
Relative percentage reduction in width 15.8
ACR50
Type I error rate 4.9 5.2
Average width of CI 11.6 9.5
Relative percentage reduction in width 17.9
ACR70
Type I error rate 4.6 5.0
Average width of CI 7.5 4.7
Relative percentage reduction in width 38.1
DAS28 <3.2
Type I error rate 5.9 5.2
Average width of CI 12.1 8.8
Relative percentage reduction in width 27.4
DAS28 <2.6
Type I error rate 5.0 5.3
Average width of CI 9.0 5.4
Relative percentage reduction in width 40.1
For each outcome, 5000 simulation replicates are used (Monte-Carlo error ±0.6%). The average width of the CIs is on the
logarithmic scale for the risk ratio and odds ratio outcomes.
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code). With minor changes, the methodology could be
applied in a similar manner to other rheumatic diseases
that use responder analyses, such as SLE, AS or PsA.
We note that in the analysis of the OSKIRA-1 data set,
the augmented binary method did not change the overall
conclusion (both binary and augmented binary methods
showed a significant difference). In many instances, how-
ever, the improved precision may provide considerable
benefits. In some cases, a trial may end with a non-defini-
tive conclusion, such as a moderate but non-significant
treatment effect. In that case, applying the augmented
binary method as a prespecified secondary analysis
would provide very useful additional information on
whether there is a significant effect or not.
This method also retains an important advantage of re-
sponder analyses over simply testing the continuous com-
ponent directly in that it allows for patients who are
withdrawn from therapy or given rescue therapy to be
treated as non-responders. An alternative method, pro-
posed by Karrison et al. [14] in the context of phase II
cancer trials, would be to test the continuous component
directly but set this component to an unfavourable level
for patients who failed for other reasons. However, this
method does not provide such easily clinically interpret-
able results. Owing to this, and the fact that it produces
outputs in a form that is well known and understandable to
rheumatologists, we believe that our method comple-
ments existing methods by giving clinically interpretable
estimates of the treatment effect for existing recognized
end points whilst making best use of the data.
Although we used a relatively large study as an illustra-
tion, the augmented binary method can be applied
successfully to smaller sample sizes, where gains in pre-
cision and power would be more influential. In the study
by Wason and Seaman [11], the method was applied to
simulated data sets with 50 patients per arm without dif-
ficulty. For smaller trials, it is possible to reduce the
number of parameters in the models; for example, by
modelling only one follow-up time instead of two.
As with any method based upon splitting patients above
or below a threshold, questions may exist about the sen-
sitivity of the results to the choice of this threshold. One
option proposed to understand this is the use of cumula-
tive distribution plots [15] (as often employed in RA trials
[16] or to understand structural progression data). The
proportion of patients with results above any threshold
can be read off these plots, and we would encourage
the use of such figures. However, this is largely a support-
ive tool, and although methods to compare distributions
exist [17], these would not typically replace a more con-
ventional analysis of response rates.
Possible extensions to the methods described here in-
clude joint modelling of individual ACR or DAS28 compo-
nents rather than purely modelling the single composite
index. The method could also allow for the simultaneous
estimation of various outcomes using multiple thresholds
based upon a single consistent model (e.g. estimating
ACR20, ACR50 and ACR70 at once). Longitudinal model-
ling of dropouts across further time points could also be
developed and could be examined under different as-
sumptions around missing data. Such longitudinal
FIG. 2 Power of standard and augmented binary methods
for different sample sizes
For each sample size, 5000 samples of that size from the
original OSKIRA-1 data set were taken at random. The
end point used is the difference in probability of achieving
DAS28 <2.6 between each arm.
FIG. 1 Scatter plot of estimated difference in response
probability from standard and augmented binary methods
Each dot represents an analysis of 200 sampled individ-
uals from the original data set. Estimated Pearson cor-
relation coefficient is 0.629 (95% CI: 0.612, 0.646).
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modelling has been completed previously in RA studies
[18], but without making use of the joint modelling of con-
tinuous scores and binary withdrawal factors as con-
sidered in the present manuscript. It may be possible to
combine these.
Although the analyses presented here suggest that the
augmented binary method could provide conventional
levels of statistical power in a smaller number of patients
than the existing methods, it is recommended that at this
time it should be considered as a supportive analysis only
and that prospective clinical trials should still be sized
according to standard methods. The augmented method
must be applied to different clinical data sets in order to
understand the typical increases in power that it may
offer. As shown in the present study, the increase in
power is variable, depending on the end point, and
would also depend on the response rates in the study
analysed. The figures shown here should be interpreted
as an illustration of the potential benefits offered and not a
general rule for choosing a sample size.
Conclusion
The augmented binary method offers a complementary
analysis method for clinical trials in RA, which makes
more efficient use of patient data whilst still reporting out-
comes in terms of currently recognized response rates.
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